Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial
Beatriz Grinsztejn(Fundação Oswaldo Cruz), Jean‐Michel Molina(Assistance Publique – Hôpitaux de Paris), Constance Delaugerre(Université Paris Cité), Nathalie De Castro(Inserm), Nêmora Tregnago Barcellos(Universidade do Vale do Rio dos Sinos), Marília Santini-Oliveira(Instituto Evandro Chagas), Carla Vorsatz(Assistance Publique – Hôpitaux de Paris), Mariza Gonçalves Morgado(Fundação Oswaldo Cruz), José Henrique Pilotto(Universidade Iguaçu), Catherine Fagard(Université de Bordeaux), Geneviève Chêne(Bordeaux Population Health), Valdiléa G. Veloso, José Valdez Madruga(Hospital Nacional Dos de Mayo), O. Patey(Centre Hospitalier Sud Francilien), Carlos Brites(Universidade Federal da Bahia), Vincent Arnold(Université de Bordeaux), Breno Santos(Hospital Nossa Senhora da Conceição)
Cited by 98
Related Papers
Prevention of HIV-1 Infection with Early Antiretroviral Therapy
|New England Journal of Medicine|2011|7k
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
|New England Journal of Medicine|2021|2.6k
Antiretroviral Therapy for the Prevention of HIV-1 Transmission
|New England Journal of Medicine|2016|1.7k
On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection
|New England Journal of Medicine|2015|1.6k